Behind every figure on this site is a person — usually a team of them — who ran the trial, followed the cohort for decades, or spent a career untangling what hormones actually do. The modern, more hopeful understanding of menopause didn't arrive on its own. It was built, study by study, and then carried into the open by clinicians willing to say plainly what the research shows.
This page is deliberately short and selective. It isn't a ranking or a complete list — the real roster runs to many more names than we could feature. We've chosen people whose work the rest of this site actually draws on, so that the names connect back to the studies you'll find cited throughout.
A note on these links. Phemthrive is independent and isn't affiliated with any clinician, product, pharmacy, or platform. Linking to someone's faculty page, publications, or public work is not an endorsement of them, their practice, or anything they sell — several of the educators below are tied to commercial ventures we take no position on. We point, as always, to the work itself.
Who built the evidence
These researchers ran the trials and led the long-running studies that this site leans on — from the Women's Health Initiative and its reanalyses to the cohorts that mapped the menopausal transition and the lab work behind the newest treatments. Each links to a faculty profile and/or a full list of their publications on PubMed.
A principal investigator of the Women's Health Initiative since its start in 1993. Her long-term follow-up and age-stratified reanalyses showed that the benefit–risk balance of hormone therapy is far more favorable for women who begin it before 60 or within ten years of menopause — the work that reframed how the alarming 2002 headlines should be read.1
Directs the Mayo Clinic Center for Women's Health and leads The Menopause Society. She chaired the panel that wrote the Society's 2022 Hormone Therapy Position Statement — the current benchmark guidance that underpins much of this site's treatment material.2
Led the ELITE trial, designed to test the "timing hypothesis" — the idea that estrogen's effect on the arteries depends on how soon after menopause it's started. ELITE found a measurable difference in early-arterial changes by timing, a cornerstone of the modern cardiovascular conversation.3
A leader in midlife women's cardiovascular and brain health. Her work in the SWAN study tied hot flashes to measurable markers of cardiovascular risk, helping reframe vasomotor symptoms as more than a quality-of-life nuisance.4
A lead investigator in SWAN, whose research established how long hot flashes actually last — a median of roughly 7.4 years, and considerably longer for some women — overturning the old assumption that they're brief and self-limiting.5
A global authority on testosterone in women. She led the international consensus statement and the large meta-analysis that together define where the evidence supports testosterone therapy for women — and, just as importantly, where it doesn't.6
Leads NIH-funded research on how the menopausal transition affects memory, mood, and the brain. Her work helps separate the real — and often time-limited — "brain fog" of the transition from lasting decline, and informs the treatment of perimenopausal depression. She served on the 2022 position-statement panel.2
A neuroscientist who uses brain imaging to study how the menopausal transition reshapes the brain and influences women's long-term Alzheimer's risk — bringing rigorous neuroimaging to questions that were long overlooked. (Her popular writing appears on our Resources page.)
An endocrinologist whose team did the human research showing that the brain signal neurokinin B can trigger hot flashes, and that blocking its receptor sharply reduces them — the science that opened the door to the new non-hormonal drugs fezolinetant and elinzanetant.7
Who carried it to the public
Research only helps if it reaches people. These clinician-educators have done the public work of translation — through books, podcasts, and writing — pushing accurate information past decades of silence and misinformation. Each links to their primary platform.
One of the most widely followed menopause educators, reaching millions with symptom education and lifestyle guidance. Author of The New Menopause, she has helped make midlife symptoms a mainstream conversation.
A relentless, evidence-first voice against menopause misinformation and unproven products. Through her newsletter The Vajenda and her books, she models how to read the science skeptically and call out hype.
A leading educator on the genitourinary syndrome of menopause and women's sexual health — areas most clinicians are never trained in. Her advocacy has helped push these topics, and the hormone-therapy label conversation, into the mainstream.
Through her popular podcast and books, she talks plainly about desire, sexual health, and hormones — reframing common midlife concerns as treatable rather than something women simply have to accept.
Author of the bestseller Grown Woman Talk, she focuses on self-advocacy and on closing the racial and generational gaps in midlife care — bringing menopause education to women too often left out of the conversation.
A breast-cancer survivor herself, she has built a distinctive focus on menopause care for cancer survivors and women at high risk — one of the most underserved corners of the field — pairing clinical training with hard-won personal insight.
The names lead back to the studies.
That's the point of this page: the people here aren't authorities to take on faith — they're the trail back to the evidence. The books and reading worth your time live on Resources; the research itself is cited throughout the rest of the site.
References
Profile links open each person's own faculty page, publication list, or website. The studies referenced in the descriptions above are listed here, and also appear in the site-wide bibliography.
- Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748–1760. doi:10.1001/jama.2024.6542. See also Manson JE, et al. JAMA. 2017;318(10):927–938. doi:10.1001/jama.2017.11217
- "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel (Faubion SS, et al.; panel incl. Maki PM). Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221–1231. doi:10.1056/NEJMoa1505241
- Thurston RC, et al. Menopausal hot flashes and carotid intima media thickness among midlife women. Stroke. 2016;47(1):12–17. doi:10.1161/STROKEAHA.115.010600
- Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN). JAMA Intern Med. 2015;175(4):531–539. doi:10.1001/jamainternmed.2014.8063
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of testosterone therapy for women. J Sex Med. 2019;16(9):1331–1337. doi:10.1016/j.jsxm.2019.07.012. See also Islam RM, et al. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5
- Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause. 2018;25(8):862–869. doi:10.1097/GME.0000000000001090. See also Jayasena CN, et al. Sci Rep. 2015;5:8466. doi:10.1038/srep08466